Published in Mol Cell Endocrinol on November 06, 2009
Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer (2013) 4.46
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid (2010) 2.05
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res (2011) 1.85
Integrin-linked kinase affects signaling pathways and migration in thyroid cancer cells and is a potential therapeutic target. Surgery (2015) 1.40
Role of estrogen in thyroid function and growth regulation. J Thyroid Res (2011) 1.19
Vitamin D, vitamin D receptor, and macroautophagy in inflammation and infection. Discov Med (2011) 1.17
Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res (2011) 1.13
Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev (2013) 1.02
TERT promoter mutations in thyroid cancer. Endocr Relat Cancer (2016) 1.01
AKT-independent PI3-K signaling in cancer - emerging role for SGK3. Cancer Manag Res (2013) 0.99
Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Oncogene (2013) 0.97
New targeted therapies for thyroid cancer. Curr Genomics (2011) 0.93
The extra domain A of fibronectin increases VEGF-C expression in colorectal carcinoma involving the PI3K/AKT signaling pathway. PLoS One (2012) 0.89
Hypoxia-inducible factor in thyroid carcinoma. J Thyroid Res (2011) 0.88
BRAF mutation in papillary thyroid carcinoma. Int J Clin Exp Med (2012) 0.88
Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma. Oncol Lett (2012) 0.87
FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocr Relat Cancer (2012) 0.87
A novel multiplex cell viability assay for high-throughput RNAi screening. PLoS One (2011) 0.87
The PI3K/Akt Pathway in Tumors of Endocrine Tissues. Front Endocrinol (Lausanne) (2016) 0.85
A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability. Oncotarget (2016) 0.84
Analysis of exosome release as a cellular response to MAPK pathway inhibition. Langmuir (2015) 0.82
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics (2014) 0.81
Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma. Oncogene (2011) 0.81
Genes related to suppression of malignant phenotype induced by Maitake D-Fraction in breast cancer cells. J Med Food (2013) 0.80
Clinical application of molecular testing of fine-needle aspiration specimens in thyroid nodules. Otolaryngol Clin North Am (2014) 0.80
The insulin resistance Grb14 adaptor protein promotes thyroid cancer ret signaling and progression. Oncogene (2011) 0.80
Selective use of sorafenib in the treatment of thyroid cancer. Drug Des Devel Ther (2016) 0.79
Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. J Clin Endocrinol Metab (2016) 0.78
Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma. Contemp Oncol (Pozn) (2014) 0.78
REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer. Oncotarget (2015) 0.78
Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification. PLoS One (2012) 0.77
New insights into the diagnosis of nodular goiter. Thyroid Res (2014) 0.77
B-Raf mutation and papillary thyroid carcinoma patients. Oncol Lett (2016) 0.76
Role of retinoids in the prevention and treatment of colorectal cancer. World J Gastrointest Oncol (2015) 0.76
RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells. Endocr Relat Cancer (2012) 0.76
The positive clinical therapeutically effects of Escin on advanced thyroid cancer. Cancer Med (2017) 0.75
miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. Oncotarget (2016) 0.75
Immune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by Hras(G12V) and Pten Loss. J Clin Cell Immunol (2016) 0.75
Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets. Front Endocrinol (Lausanne) (2012) 0.75
MicroRNAs in the thyroid. Best Pract Res Clin Endocrinol Metab (2016) 0.75
Downregulation of LSD1 suppresses the proliferation, tumorigenicity and invasion of papillary thyroid carcinoma K1 cells. Oncol Lett (2016) 0.75
Clinicopathological Characteristics and Prognosis of Papillary Thyroid Carcinoma in Naturally Menopausal Women with Various Durations of Premenarche, Reproductive Periods, and Postmenopausal Stages. Int J Endocrinol (2017) 0.75
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
TOR signaling in growth and metabolism. Cell (2006) 35.29
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J (1996) 16.68
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Pten is essential for embryonic development and tumour suppression. Nat Genet (1998) 13.41
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2006) 12.23
Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science (2001) 11.22
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 10.98
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 10.71
SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell (2006) 10.50
PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell (2005) 8.22
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer (2006) 7.53
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
Role of translocation in the activation and function of protein kinase B. J Biol Chem (1997) 7.29
Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem (2001) 7.10
The multiple roles of PTEN in tumor suppression. Cell (2000) 6.71
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44
Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 5.31
TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science (2003) 5.25
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol (2008) 5.04
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol (2005) 5.00
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4.83
Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest (2003) 4.79
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A (1991) 4.66
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res (2001) 4.63
Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A (1987) 4.56
Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A (2000) 4.55
Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res (2007) 4.48
Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci (2004) 4.40
Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med (2008) 4.39
Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene (1998) 4.31
Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature (2009) 4.21
Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem (2004) 4.01
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 3.98
Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet (2002) 3.89
PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science (2000) 3.87
Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer (2006) 3.83
Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell (2005) 3.78
Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol (2009) 3.73
Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56
Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci U S A (1996) 3.50
Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci (2005) 3.45
Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene (2008) 3.31
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 3.24
Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J Biol Chem (1996) 2.99
Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem (1999) 2.89
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab (2008) 2.89
Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem (2000) 2.86
Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res (2004) 2.84
The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev (2006) 2.76
PTEN, more than the AKT pathway. Carcinogenesis (2007) 2.70
A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer (2008) 2.63
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res (2007) 2.61
Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol (2008) 2.58
Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J (2001) 2.55
Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res (2001) 2.51
Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci U S A (2000) 2.49
Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci U S A (2000) 2.48
Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci U S A (2006) 2.41
The nuclear affairs of PTEN. J Cell Sci (2008) 2.34
Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg (2007) 2.28
Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2. Oncogene (1999) 2.20
Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol (2001) 2.18
Genomic alterations in tumor stroma. Cancer Res (2009) 2.18
Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid (2002) 2.18
AKT signaling in normal and malignant cells. Oncogene (2005) 2.14
Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science (2001) 2.11
Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res (2005) 2.10
Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res (1997) 2.06
The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res (2007) 2.06
Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol (2000) 2.05
Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A (2009) 2.02
Scaffolding function of PAK in the PDK1-Akt pathway. Nat Cell Biol (2008) 2.02
Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol Cell Biol (2006) 2.01
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab (2008) 1.95
Opposing roles for Akt1 and Akt2 in Rac/Pak signaling and cell migration. J Biol Chem (2006) 1.94
Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci (2007) 1.90
Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet (2004) 1.85
Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A (2007) 1.84
Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal (2008) 1.81
Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene (2001) 1.70
Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. Oncogene (1999) 1.67
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab (2007) 1.66
Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle (2007) 1.65
Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene (2005) 1.65
Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res (2009) 1.65
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc Natl Acad Sci U S A (2006) 1.62
AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology (2005) 1.56
Akt mediates Rac/Cdc42-regulated cell motility in growth factor-stimulated cells and in invasive PTEN knockout cells. Curr Biol (2001) 1.56
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol (2009) 3.73
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol (2010) 2.96
Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell (2005) 2.73
Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol (2011) 2.59
Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A (2009) 2.20
Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A (2007) 1.84
Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet (2012) 1.81
Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer. J Clin Endocrinol Metab (2010) 1.65
AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology (2005) 1.56
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am (2008) 1.41
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab (2008) 1.40
Paternal imprinting of Galpha(s) in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a. Biochem Biophys Res Commun (2002) 1.36
A mouse model of albright hereditary osteodystrophy generated by targeted disruption of exon 1 of the Gnas gene. Endocrinology (2005) 1.34
2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Mol Pharmacol (2007) 1.29
Akt controls vascular smooth muscle cell proliferation in vitro and in vivo by delaying G1/S exit. Circ Res (2003) 1.27
The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. J Clin Endocrinol Metab (2010) 1.22
Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma. Thyroid (2013) 1.20
Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet (2011) 1.19
AKT in thyroid tumorigenesis and progression. Endocrinology (2006) 1.17
Akt1 contains a functional leucine-rich nuclear export sequence. Biochem Biophys Res Commun (2005) 1.15
Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab (2005) 1.14
SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility. J Clin Endocrinol Metab (2013) 1.12
Regulation of actin function by protein kinase A-mediated phosphorylation of Limk1. EMBO Rep (2009) 1.08
"Thyroid cancer" cell line misidentification: a time for proactive change. J Clin Endocrinol Metab (2008) 1.05
Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy. Otolaryngol Head Neck Surg (2005) 1.02
Epidermal growth factor inhibition of c-Myc-mediated apoptosis through Akt and Erk involves Bcl-xL upregulation in mammary epithelial cells. Exp Cell Res (2003) 1.00
Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid (2002) 1.00
Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma. Carcinogenesis (2011) 0.99
Genetic predisposition for nonmedullary thyroid cancer. Horm Cancer (2014) 0.99
KiSS-1/G protein-coupled receptor 54 metastasis suppressor pathway increases myocyte-enriched calcineurin interacting protein 1 expression and chronically inhibits calcineurin activity. J Clin Endocrinol Metab (2005) 0.98
Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab (2006) 0.97
Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. Eur J Endocrinol (2004) 0.95
17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels. J Clin Endocrinol Metab (2004) 0.95
Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab (2003) 0.94
MicroRNA signature in thyroid fine needle aspiration cytology applied to "atypia of undetermined significance" cases. Thyroid (2011) 0.93
Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion. Endocr Relat Cancer (2010) 0.93
Frequency of germline PTEN mutations in differentiated thyroid cancer. Thyroid (2011) 0.92
Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Mol Carcinog (2004) 0.90
Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice. J Clin Endocrinol Metab (2014) 0.88
Metastatic mechanisms in follicular cell-derived thyroid cancer. Endocr Relat Cancer (2013) 0.88
Thyrocytes express a functional toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto's autoimmune thyroiditis. Mol Endocrinol (2005) 0.88
Regulator of calcineurin 1 modulates cancer cell migration in vitro. Clin Exp Metastasis (2009) 0.84
High-sensitivity TFA-free LC-MS for profiling histones. Proteomics (2011) 0.84
Combined use of perioperative TSH-stimulated (18)F-FDG PET/CT imaging and gamma probe radioguided surgery to localize and verify resection of iodine scan-negative recurrent thyroid carcinoma. Laryngoscope (2008) 0.84
Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. Endocr Relat Cancer (2012) 0.84
Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab (2002) 0.84
Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Endocr Relat Cancer (2007) 0.83
Modulation of sodium iodide symporter expression and function by LY294002, Akti-1/2 and Rapamycin in thyroid cells. Endocr Relat Cancer (2012) 0.83
Subclinical thyroid dysfunction--can there be a consensus about the consensus? J Clin Endocrinol Metab (2005) 0.83
Akt: a potential target for thyroid cancer therapy. Curr Drug Targets Immune Endocr Metabol Disord (2004) 0.82
Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration. J Clin Endocrinol Metab (2013) 0.81
PTEN lipid phosphatase activity and proper subcellular localization are necessary and sufficient for down-regulating AKT phosphorylation in the nucleus in Cowden syndrome. J Clin Endocrinol Metab (2012) 0.81
A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin Endocrinol Metab (2015) 0.80
Molecular detection of thyroid cancer: differentiating "signal" and "noise" in clinical assays. J Clin Endocrinol Metab (2004) 0.80
Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinoma. J Clin Endocrinol Metab (2011) 0.79
Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw (2015) 0.78
Frontiers in thyroid cancer: December 2009. Thyroid (2009) 0.78
Apigenin in combination with Akt inhibition significantly enhances thyrotropin-stimulated radioiodide accumulation in thyroid cells. Thyroid (2014) 0.77
Evaluation of adult papillary thyroid carcinomas by comparative genomic hybridization and microsatellite instability analysis. Cancer Genet Cytogenet (2002) 0.77
Localization of CaSR antagonists in CaSR-expressing medullary thyroid cancer. J Clin Endocrinol Metab (2013) 0.76
Do tumor characteristics predict risk of malignancy in thyroid nodules with indeterminate cytology? Nat Clin Pract Endocrinol Metab (2009) 0.75
Ernest L. Mazzaferri, SR., MD 1936-2013. Trans Am Clin Climatol Assoc (2015) 0.75
Linking oncogenes to invasion in thyroid cancer. Cell Cycle (2011) 0.75
Development of a calcium-sensing receptor molecular imaging agent. Surgery (2013) 0.75
Current therapy for childhood thyroid cancer: optimal surgery and the legacy of king pyrrhus. Ann Surg Oncol (2003) 0.75
A novel PTEN mutation in Cowden syndrome is associated with a mixed degenerative-erosive arthritic process: potential molecular pathogenic mechanisms. Am J Med Genet A (2007) 0.75